Ascentage Pharma Group International (NASDAQ:AAPG) Reaches New 52-Week Low - Here's What Happened

Key Points

• Ascentage Pharma shares fell to a new 52-week low of $16.23, down from the prior close of $17.10, while trading volume reached 7,070 shares.
• Despite the decline, analysts remain bullish: the stock has a consensus “Buy” rating and an average price target of $46.43, with recent targets of $45 and $48.
• The clinical-stage biopharmaceutical company reported a quarterly loss of $0.65 per share on $22.24 million in revenue, and analysts expect a full-year loss of $2.26 per share.

Shares of Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report) hit a new 52-week low during trading on Tuesday . The stock traded as low as $16.23 and last traded at $16.23, with a volume of 7070 shares. The stock had previously closed at $17.10.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on AAPG shares. Raymond James Financial reaffirmed a "buy" rating on shares of Ascentage Pharma Group International in a report on Wednesday, June 10th. BTIG Research restated a "buy" rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Finally, B. Riley Financial started coverage on Ascentage Pharma Group International in a research note on Wednesday, June 10th. They issued a "buy" rating and a $45.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $46.43.

Ascentage Pharma Group International Price Performance

The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09. The firm has a 50 day moving average price of $18.23 and a 200-day moving average price of $20.91.

Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report) last released its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The firm had revenue of $22.24 million during the quarter. Research analysts expect that Ascentage Pharma Group International - Unsponsored ADR will post -2.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC bought a new stake in shares of Ascentage Pharma Group International in the 3rd quarter worth about $383,000. Hsbc Holdings PLC bought a new position in Ascentage Pharma Group International during the 2nd quarter valued at about $391,000. Finally, UBS Group AG grew its holdings in Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company's stock valued at $716,000 after purchasing an additional 10,988 shares during the last quarter.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source